Severe Male Fertility Impairment Tied to Increased Risk for Nonreproductive Cancers
via HealthDayTUESDAY, April 21, 2026 -- Men with severely impaired fertility may have an increased risk for colorectal and thyroid cancer, according to a study published online Feb. 21 in the European Journal of Epidemiology.
Peter Zarén, from Lund University in Sweden, and colleagues compared the risk for developing nonreproductive cancers in men achieving paternity through assisted reproduction to the risk for those conceiving naturally. The analysis included nearly 1.14 million first-time fathers (January 1994 to December 2014) followed from the time of conception until the date of cancer diagnosis, death, or end of follow-up.
The researchers found that fathers conceiving by intracytoplasmic sperm injection or donated spermatozoa versus those conceiving spontaneously had an increased risk for nonreproductive cancers (adjusted hazard ratio [aHR], 1.3), particularly colon (aHR, 1.7), rectum (aHR, 1.8), and thyroid (aHR, 3.3) cancer.
"These findings are important from a public health perspective given that cancers of the colon and rectum, as well as thyroid cancer, are on the rise among younger people," coauthor Angel Elenkov, Ph.D., also from Lund University, said in a statement. "These cancers could be prevented through early screening."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-04-22 02:09
Read more
- Children’s Activity Cubes Recalled Over Choking Hazard Risk
- Former Surgeon General Backs CDC Nominee, But Questions Remain on Vaccines
- Adenoidectomy, Tonsillectomy in Childhood Tied to Risk for Adult Chronic Rhinosinusitis
- Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
- Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-Positive NSCLC
- Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions